The aim of this study was to analyze prevalence ischaemic and bleeding events in patients undergoing TAVI in according to management of antithrombotic therapy
Methods: A total of 637 consecutive patients with aortic stenosis undergoing TAVI were evaluated, between April 2008 and December 201, on base to antithrombotic/antiplatelet therapy received at discharge.
Results: The patients were characterized by had a HAS-BLED score 2.8± 1.1, CHADS2 3.35±1.0 and CHAD2-Vasc score 5.08±1.2. In 53 patiens (8.3%) were treated in monotherapy with an antiplatelet, dual antiplatelet in 424 (60.6%), (3.2%) triple therapy in 29 patients (4.6%) and 131 patients (20.6%) with oral anticoagulant plus a thienopyridine. We found not differences in mortality in according to antithrombotic therapy, respectively: 52.9% vs. 37.4% vs. 34.5% vs 47, [HR= 1.087 (95% CI 0.912-1.297), p=0.350], There were no differences in stroke 15.1% vs. 7.3% vs. 13.8% vs 10%, [HR=1.029 (95% CI 0.767-1.392), p=0.854], major bleeding 5.7% vs. 3.8% vs. 3.4% vs. 6.1% %, [HR=1.167 (95% CI 0.782-1.741), p=0.449], and myocardial infarction 1.9% vs. 3.8% vs. 3.4% vs. 0.8%, %, [HR=0.669 (95% CI 0.366-1.225), p=0.193].
Conclusions: in this study there was no differences in rate of mortality or isquemic and hemorragic events, although there were trend to higher rate of mortality in patients with only antiplatelet and anticoagulant plus thienopyridine.